Business
RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium
The accepted abstracts support RenovoRx’s lead oncology product candidate, RenovoGem™, and its novel therapy platform, RenovoTAMP®, for the treatment of
About this update from Renovorx, Inc.
[{"type":"text","content":"\nThe accepted abstracts support RenovoRx’s lead oncology product candidate, RenovoGem™, and its novel therapy platform, RenovoTAMP®, for the treatment of difficult-to-treat cancers.\n\n LOS ALTOS, Calif.--(BUSINESS WIRE)--\nRenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced the acceptance of four clinical data abstracts supporting its lead oncology product candidate, RenovoGem, and its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform to be presented at the 2023 ASCO Gastrointestinal Cancers Symposium (ASCO GI). The Symposium is to be held on January 19-21, 2023 in San Francisco, California and online.\n\nRenovoGem (gemcitabine, an FDA-approved chemotherapy, delivered via the Company’s proprietary delivery system) utilizes pressure mediated delivery of drug across the arterial wall to bathe tumor tissue in chemotherapy via RenovoTAMP. RenovoGem is currently being evaluated in a Phase III clinical trial in Locally Advanced Pancreatic Cancer (LAPC) patients and the Company plans to investigate RenovoGem in extrahepatic Cholangiocarcinoma (eCCA), beginning in the first half of 2023.\n\n\"These research presentations will mark the beginning of a significant year at RenovoRx,” said Shaun Bagai, CEO of RenovoRx. “We anticipate continued strong progress on the TIGeR-PaC study with our most significant milestone to date: the first prospective interim analysis of TIGeR-PaC. We also plan to launch a clinical program in extrahepatic Cholangiocarcinoma (bile duct cancer), the second clinical indication for RenovoGem and the RenovoTAMP platform.”\n\n“We are excited to present clinical research data generated by some of our investigators of the TIGeR-PaC study at ASCO GI,” said Ramtin Agah, MD, Chief Medical Officer and Founder of RenovoRx. \"These abstracts cover topics relevant to treatment of patients participating in the TIGeR-PaC study. Furthermore, we will also share data regarding the difference in systemic level of gemcitabine using our therapy platform versus the conventional treatment approach for LAPC which is central to our goal of presumed increased efficacy for RenovoTAMP with less systemic side effects.”\n\nPoster Presentations Details:\n\nTitle: Incidence and Clinical Characteristics of Patients with ...